Clinical Depression

ISSN: 2572-0791

Open Access

Zhengyi Lee

Department of Neurology, Wuhu Second Peoples Hospital, China

  • Mini Review   
    Antidepressant Drugs: Basic and Clinical Evidence and COVID-19
    Author(s): Zhengyi Lee*

    There is evidence to back up the idea that some antidepressants can lower levels of various cytokines in both humans and animals, and more recently, it has been revealed that some antidepressant have antiviral effect against SARS-CoV-2. The purpose of this narrative review is to assess the potential value of antidepressants in the management of COVID-19 infection as well as the potential advantages and disadvantages of antidepressant therapy for COVID-19 infections and mental problems. An analysis of the recent literature was done to determine the place of antidepressant drugs in the care of COVID-19 patients. Additionally, two phase II studies investigating fluvoxamine that were published and showed promising results against a placebo for clinical deterioration and hospitalisation rate. The first stages of seven ongoing clinical trials are examining fluvoxamin.. Read More»
    DOI: 10.37421/2572-0791.2022.8.31

    Abstract HTML PDF

50+ Million Readerbase

Journal Highlights

Google Scholar citation report
Citations: 74

Clinical Depression received 74 citations as per Google Scholar report

Indexed In

arrow_upward arrow_upward